Mesenchymal stem cells and adaptive immune responses

2015 ◽  
Vol 168 (2) ◽  
pp. 147-153 ◽  
Author(s):  
Wei Cao ◽  
Kai Cao ◽  
Jianchang Cao ◽  
Ying Wang ◽  
Yufang Shi
Blood ◽  
2015 ◽  
Vol 125 (25) ◽  
pp. 3886-3895 ◽  
Author(s):  
Jeremy A. Goettel ◽  
Subhabrata Biswas ◽  
Willem S. Lexmond ◽  
Ada Yeste ◽  
Laura Passerini ◽  
...  

Key Points Improved adaptive immune responses in humanized mice lacking murine MHC II and expressing human HLADR1. NOD.PrkdcscidIl2rγ−/−H2-Ab1−/− Tg(HLA-DR1) mice reconstituted with hematopoietic stem cells from an IPEX syndrome patient develop fatal autoimmunity.


2019 ◽  
Vol 14 (1) ◽  
pp. 43-51 ◽  
Author(s):  
Mahboobeh Razmkhah ◽  
Shabnam Abtahi ◽  
Abbas Ghaderi

Mesenchymal Stem Cells [MSCs] are a heterogeneous population of fibroblast-like cells which maintain self-renewability and pluripotency. Many studies have demonstrated the immunomodulatory effects of MSCs on the innate and adaptive immune cells. As a result of interactions with tumor cells, microenvironment and immune-stimulating milieu, MSCs contribute to tumor progression by several mechanisms, including sustained proliferative signal in cancer stem cells [CSCs], inhibition of tumor cell apoptosis, transition to tumor-associated fibroblasts [TAFs], promotion of angiogenesis, stimulation of epithelial-mesenchymal transition [EMT], suppression of immune responses, and consequential promotion of tumor metastasis. Here, we present an overview of the latest findings on Janusfaced roles that MSCs play in the tumor microenvironment [TME], with a concise focus on innate and adaptive immune responses.


Sign in / Sign up

Export Citation Format

Share Document